Article Abstract

Cefazolin or nafcillin? —a commentary on the optimal treatment of methicillin-susceptible Staphylococcus aureus bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins

Authors: Paul O. Lewis, Kelly L. Covert, David B. Cluck

Abstract

Staphylococcus aureus bacteremia represents significant burden on the healthcare system with early mortality rates as high as 60% and more recent studies suggesting mortality rates of 10–30% (1,2). While methicillin-resistant Staphylococcus aureus (MRSA) has garnered much of the attention due to higher mortality rates and treatment difficulties, the optimal treatment of methicillin-susceptible Staphylococcus aureus (MSSA) is still in question (1).